Pub Date : 1984-01-01DOI: 10.1515/dmdi.1984.5.1.53
B H Stock
The results of both isolated tissue and whole animal experimentation, whilst showing some unexplored inconsistencies, suggest that late pregnancy is associated with a reduced ability of the liver to metabolise foreign compounds. The mechanism of this reduced capacity and the physiological reason for it are unclear but such change does have implication for therapeutic response in pregnancy. Available results from the limited and often poorly structured studies of drug levels in pregnant women neither prove nor disprove the existence of similar changes in hepatic monooxygenase activity during human pregnancy.
{"title":"Hepatic drug metabolism in pregnancy.","authors":"B H Stock","doi":"10.1515/dmdi.1984.5.1.53","DOIUrl":"https://doi.org/10.1515/dmdi.1984.5.1.53","url":null,"abstract":"<p><p>The results of both isolated tissue and whole animal experimentation, whilst showing some unexplored inconsistencies, suggest that late pregnancy is associated with a reduced ability of the liver to metabolise foreign compounds. The mechanism of this reduced capacity and the physiological reason for it are unclear but such change does have implication for therapeutic response in pregnancy. Available results from the limited and often poorly structured studies of drug levels in pregnant women neither prove nor disprove the existence of similar changes in hepatic monooxygenase activity during human pregnancy.</p>","PeriodicalId":79248,"journal":{"name":"Quarterly reviews on drug metabolism and drug interactions","volume":"5 1","pages":"53-81"},"PeriodicalIF":0.0,"publicationDate":"1984-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1515/dmdi.1984.5.1.53","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"17458295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Metabolism and pharmacokinetics of hydroxyethylated rutosides in animals and man.","authors":"L P Balant, M Wermeille, L A Griffiths","doi":"10.1515/dmdi.1984.5.1.1","DOIUrl":"https://doi.org/10.1515/dmdi.1984.5.1.1","url":null,"abstract":"","PeriodicalId":79248,"journal":{"name":"Quarterly reviews on drug metabolism and drug interactions","volume":"5 1","pages":"1-24"},"PeriodicalIF":0.0,"publicationDate":"1984-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1515/dmdi.1984.5.1.1","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"17458294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1984-01-01DOI: 10.1515/dmdi.1984.5.1.25
W Greene
In summary, cimetidine is a potent inhibitor of liver microsomal activity, which may also decrease hepatic blood flow. Other effects of the drug include inhibition of gastric secretion and intrinsic toxic properties. These effects, combined with the common use of cimetidine in clinical practice, make the risk of adverse drug interactions a relatively frequent risk in the clinical setting. Although a multitude of interactions with cimetidine has been evaluated, many of these are incompletely described or understood. At the present time, a potentially significant alteration of absorption appears to exist with only ketoconazole, elemental iron, vitamin B12 (long-term therapy), and pancreatic enzyme supplements (increased activity). Significant metabolic inhibition or decreased excretion appears to exist with warfarin, propranolol, theophylline, phenytoin, quinidine, possibly lidocaine and procainamide, and certain benzodiazepines. Other potential, but less well ascertained interactions may involve the narcotic analgesics, caffeine, ethanol, pentobarbital, imipramine, chlormethiazole, and metronidazole. In these settings, the clinician must be aware of interaction potential, and astutely monitor the patient during combination therapy. Other data indicate that concomitant administration of antacids may reduce the absorption of cimetidine, that the drug may protect against the toxic effects of acetaminophen overdose, and that combination with certain other myelosuppressants may carry a significant risk. Thus, in regard to these reports, cimetidine is a drug with complex effects on the absorption, elimination, and toxicity of other drugs. When used in the setting of multiple drug therapy, the clinician must be alert to potentially increased or decreased effects of the drugs mentioned in this review. In addition, one must be aware that other hepatically metabolised agents not mentioned here may be affected by the addition of cimetidine therapy. Because of the therapeutic successes demonstrated in the treatment of various disorders with cimetidine, one cannot disregard this agent. Thus, the responsibility for understanding and monitoring for the complex effects of this drug falls with the practicing physician.
{"title":"Drug interactions involving cimetidine--mechanisms, documentation, implications.","authors":"W Greene","doi":"10.1515/dmdi.1984.5.1.25","DOIUrl":"https://doi.org/10.1515/dmdi.1984.5.1.25","url":null,"abstract":"<p><p>In summary, cimetidine is a potent inhibitor of liver microsomal activity, which may also decrease hepatic blood flow. Other effects of the drug include inhibition of gastric secretion and intrinsic toxic properties. These effects, combined with the common use of cimetidine in clinical practice, make the risk of adverse drug interactions a relatively frequent risk in the clinical setting. Although a multitude of interactions with cimetidine has been evaluated, many of these are incompletely described or understood. At the present time, a potentially significant alteration of absorption appears to exist with only ketoconazole, elemental iron, vitamin B12 (long-term therapy), and pancreatic enzyme supplements (increased activity). Significant metabolic inhibition or decreased excretion appears to exist with warfarin, propranolol, theophylline, phenytoin, quinidine, possibly lidocaine and procainamide, and certain benzodiazepines. Other potential, but less well ascertained interactions may involve the narcotic analgesics, caffeine, ethanol, pentobarbital, imipramine, chlormethiazole, and metronidazole. In these settings, the clinician must be aware of interaction potential, and astutely monitor the patient during combination therapy. Other data indicate that concomitant administration of antacids may reduce the absorption of cimetidine, that the drug may protect against the toxic effects of acetaminophen overdose, and that combination with certain other myelosuppressants may carry a significant risk. Thus, in regard to these reports, cimetidine is a drug with complex effects on the absorption, elimination, and toxicity of other drugs. When used in the setting of multiple drug therapy, the clinician must be alert to potentially increased or decreased effects of the drugs mentioned in this review. In addition, one must be aware that other hepatically metabolised agents not mentioned here may be affected by the addition of cimetidine therapy. Because of the therapeutic successes demonstrated in the treatment of various disorders with cimetidine, one cannot disregard this agent. Thus, the responsibility for understanding and monitoring for the complex effects of this drug falls with the practicing physician.</p>","PeriodicalId":79248,"journal":{"name":"Quarterly reviews on drug metabolism and drug interactions","volume":"5 1","pages":"25-51"},"PeriodicalIF":0.0,"publicationDate":"1984-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1515/dmdi.1984.5.1.25","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"17218650","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1982-01-01DOI: 10.1515/dmdi.1982.4.2-3.123
R Makowski, R Davies, G G Gibson
{"title":"Species differences in cytochromes P450 and their corresponding messenger RNA's.","authors":"R Makowski, R Davies, G G Gibson","doi":"10.1515/dmdi.1982.4.2-3.123","DOIUrl":"https://doi.org/10.1515/dmdi.1982.4.2-3.123","url":null,"abstract":"","PeriodicalId":79248,"journal":{"name":"Quarterly reviews on drug metabolism and drug interactions","volume":"4 2-3","pages":"123-70"},"PeriodicalIF":0.0,"publicationDate":"1982-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1515/dmdi.1982.4.2-3.123","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"17819925","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1982-01-01DOI: 10.1515/dmdi.1982.4.2-3.99
J R Fry
Isolated hepatocytes are being increasingly used in drug metabolism studies since they possess many of the attributes of both in vitro and in vivo systems. This paper reviews recent work on this use of isolated hepatocytes, with particular emphasis on their value in the study of (a) species and organ differences in xenobiotic metabolism, (b) the relation of metabolism to toxicity and (c) the balance of Phase I/Phase II metabolism.
{"title":"The metabolism of drugs by isolated hepatocytes.","authors":"J R Fry","doi":"10.1515/dmdi.1982.4.2-3.99","DOIUrl":"https://doi.org/10.1515/dmdi.1982.4.2-3.99","url":null,"abstract":"<p><p>Isolated hepatocytes are being increasingly used in drug metabolism studies since they possess many of the attributes of both in vitro and in vivo systems. This paper reviews recent work on this use of isolated hepatocytes, with particular emphasis on their value in the study of (a) species and organ differences in xenobiotic metabolism, (b) the relation of metabolism to toxicity and (c) the balance of Phase I/Phase II metabolism.</p>","PeriodicalId":79248,"journal":{"name":"Quarterly reviews on drug metabolism and drug interactions","volume":"4 2-3","pages":"99-122"},"PeriodicalIF":0.0,"publicationDate":"1982-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1515/dmdi.1982.4.2-3.99","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"17819928","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Specific covalent binding and toxicity of aliphatic halogenated xenobiotics.","authors":"R J Laib","doi":"10.1515/dmdi.1982.4.1.1","DOIUrl":"https://doi.org/10.1515/dmdi.1982.4.1.1","url":null,"abstract":"","PeriodicalId":79248,"journal":{"name":"Quarterly reviews on drug metabolism and drug interactions","volume":"4 1","pages":"1-48"},"PeriodicalIF":0.0,"publicationDate":"1982-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1515/dmdi.1982.4.1.1","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"17815078","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1982-01-01DOI: 10.1515/dmdi.1982.4.2-3.171
W Lenk, H Sterzl
{"title":"Differences in the ferrihemoglobin-forming capabilities and carcinogenicities between monocyclic and polycyclic N-acylarylamines and their derivatives.","authors":"W Lenk, H Sterzl","doi":"10.1515/dmdi.1982.4.2-3.171","DOIUrl":"https://doi.org/10.1515/dmdi.1982.4.2-3.171","url":null,"abstract":"","PeriodicalId":79248,"journal":{"name":"Quarterly reviews on drug metabolism and drug interactions","volume":"4 2-3","pages":"171-236"},"PeriodicalIF":0.0,"publicationDate":"1982-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1515/dmdi.1982.4.2-3.171","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"17819926","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1982-01-01DOI: 10.1515/dmdi.1982.4.2-3.237
A Assandri, A Omodei-Salé, G Galliani
{"title":"A new class of non-hormonal contragestational agents: pharmacodynamic-pharmacokinetic relationships.","authors":"A Assandri, A Omodei-Salé, G Galliani","doi":"10.1515/dmdi.1982.4.2-3.237","DOIUrl":"https://doi.org/10.1515/dmdi.1982.4.2-3.237","url":null,"abstract":"","PeriodicalId":79248,"journal":{"name":"Quarterly reviews on drug metabolism and drug interactions","volume":"4 2-3","pages":"237-61"},"PeriodicalIF":0.0,"publicationDate":"1982-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1515/dmdi.1982.4.2-3.237","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"17819927","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1982-01-01DOI: 10.1515/dmdi.1982.4.4.289
M Ebadi, C F Gessert, A Al-Sayegh
In this review it has been pointed out that vitamin B6 and its vitamers can be involved in many interactions with a number of drugs, as well as with the actions of various endocrines and neurotransmitters. Nutritional deficiencies, especially of vitamins and proteins, can affect the manner in which drugs undergo biotransformation, and thereby may also modify the therapeutic efficacy of certain drugs. The differences between nutritional vitamin B6 deficiency and the hereditary disorder producing pyridoxine dependency are discussed. In addition to a pyridoxine deficiency being able to adversely affect drug actions, the improper supplementation with vitamin B6 can in some instances also adversely affect drug efficacy. A decrease by pyridoxine in the efficacy of levodopa used in the treatment of Parkinsonism is an example. The interrelationships and enzymatic interconversions among pyridoxine vitamers, both phosphorylated and non-phosphorylated, are briefly discussed, particularly regarding their pharmacokinetic properties. The ways in which the normal biochemical functions of vitamin B6 may be interfered with by various drugs are reviewed. (1) The chronic administration of isoniazid for the prevention or treatment of tuberculosis can produce peripheral neuropathy which can be prevented by the concurrent administration of pyridoxine. An acute toxic overdose of isoniazid causes generalized convulsions, and the intravenous administration of pyridoxine hydrochloride will prevent or stop these seizures. (2) The acute ingestion of excessive monosodium glutamate will, in some individuals, cause a group of symptoms including among others headache, weakness, stiffness, and heartburn, collectively known as the 'Chinese Restaurant Syndrome.' These symptoms can be prevented by prior supplementation with vitamin B6. The beneficial effect is ascribed to the correction of a deficiency in the activity of glutamic oxaloacetic transaminase, an enzyme that is dependent on pyridoxal phosphate. Some interesting relationships are pointed out between vitamin B6, picolinic acid, and zinc. It is postulated that the intestinal absorption of zinc is facilitated by picolinic acid, a metabolite of tryptophan. The derivation of picolinic acid from tryptophan depends on the action of the enzyme kynureninase, which is dependent on pyridoxal phosphate; therefore, the adequate absorption of zinc is indirectly dependent on an adequate supply of vitamin B6. The formation of pyridoxal phosphate, on the other hand, appears to be indirectly dependent on Zn2++ which activates pyridoxal kinase.(ABSTRACT TRUNCATED AT 400 WORDS)
{"title":"Drug-pyridoxal phosphate interactions.","authors":"M Ebadi, C F Gessert, A Al-Sayegh","doi":"10.1515/dmdi.1982.4.4.289","DOIUrl":"https://doi.org/10.1515/dmdi.1982.4.4.289","url":null,"abstract":"<p><p>In this review it has been pointed out that vitamin B6 and its vitamers can be involved in many interactions with a number of drugs, as well as with the actions of various endocrines and neurotransmitters. Nutritional deficiencies, especially of vitamins and proteins, can affect the manner in which drugs undergo biotransformation, and thereby may also modify the therapeutic efficacy of certain drugs. The differences between nutritional vitamin B6 deficiency and the hereditary disorder producing pyridoxine dependency are discussed. In addition to a pyridoxine deficiency being able to adversely affect drug actions, the improper supplementation with vitamin B6 can in some instances also adversely affect drug efficacy. A decrease by pyridoxine in the efficacy of levodopa used in the treatment of Parkinsonism is an example. The interrelationships and enzymatic interconversions among pyridoxine vitamers, both phosphorylated and non-phosphorylated, are briefly discussed, particularly regarding their pharmacokinetic properties. The ways in which the normal biochemical functions of vitamin B6 may be interfered with by various drugs are reviewed. (1) The chronic administration of isoniazid for the prevention or treatment of tuberculosis can produce peripheral neuropathy which can be prevented by the concurrent administration of pyridoxine. An acute toxic overdose of isoniazid causes generalized convulsions, and the intravenous administration of pyridoxine hydrochloride will prevent or stop these seizures. (2) The acute ingestion of excessive monosodium glutamate will, in some individuals, cause a group of symptoms including among others headache, weakness, stiffness, and heartburn, collectively known as the 'Chinese Restaurant Syndrome.' These symptoms can be prevented by prior supplementation with vitamin B6. The beneficial effect is ascribed to the correction of a deficiency in the activity of glutamic oxaloacetic transaminase, an enzyme that is dependent on pyridoxal phosphate. Some interesting relationships are pointed out between vitamin B6, picolinic acid, and zinc. It is postulated that the intestinal absorption of zinc is facilitated by picolinic acid, a metabolite of tryptophan. The derivation of picolinic acid from tryptophan depends on the action of the enzyme kynureninase, which is dependent on pyridoxal phosphate; therefore, the adequate absorption of zinc is indirectly dependent on an adequate supply of vitamin B6. The formation of pyridoxal phosphate, on the other hand, appears to be indirectly dependent on Zn2++ which activates pyridoxal kinase.(ABSTRACT TRUNCATED AT 400 WORDS)</p>","PeriodicalId":79248,"journal":{"name":"Quarterly reviews on drug metabolism and drug interactions","volume":"4 4","pages":"289-331"},"PeriodicalIF":0.0,"publicationDate":"1982-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1515/dmdi.1982.4.4.289","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"17154833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1982-01-01DOI: 10.1515/dmdi.1982.4.1.49
J L Plummer, M J Cousins, P Hall
{"title":"Volatile anaesthetic metabolism and acute toxicity.","authors":"J L Plummer, M J Cousins, P Hall","doi":"10.1515/dmdi.1982.4.1.49","DOIUrl":"https://doi.org/10.1515/dmdi.1982.4.1.49","url":null,"abstract":"","PeriodicalId":79248,"journal":{"name":"Quarterly reviews on drug metabolism and drug interactions","volume":"4 1","pages":"49-98"},"PeriodicalIF":0.0,"publicationDate":"1982-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1515/dmdi.1982.4.1.49","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"17815079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}